• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Vertex Pharma stock drops 5% after company predicts slower Q3

    Vertex Pharma stock drops 5% after company predicts slower Q3

  2. Global AntiFungal Agents Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Gilead, Kramer Labs - Research and Markets

    Global AntiFungal Agents Market Report 2016-2022 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Gilead, Kramer Labs - Research and Markets

  3. Kroll Bond Rating Agency Assigns Preliminary Ratings to MSBAM 2016-C30

    Kroll Bond Rating Agency Assigns Preliminary Ratings to MSBAM 2016-C30

  4. Nasdaq nails major support, S&P 500 holds the range

    Nasdaq nails major support, S&P 500 holds the range

  5. Nasdaq nails major support, S&P 500 holds the -2-

    Nasdaq nails major support, S&P 500 holds the -2-

  6. Decibel Therapeutics Expands Leadership Team

    Decibel Therapeutics Expands Leadership Team

  7. Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine

    Moderna Enters New Growth Phase with Closing of $474 Million Equity Financing and its First BARDA Grant for up to $125 Million for Zika mRNA Vaccine

  8. Five Consensus Views that Could Prove Wrong in 2015

    Options on this firm's blockbuster cost a little but pay off big.

  9. Reinvent Your Practice: Alternatives to Traditional Succession Planning

    Following is a roundup of stocks that recently jumped to 5 stars in the last week. By way of background, we award a stock 5 stars when it trades at a suitably large discount--i.e., a margin of safety--to our fair value estimate. Thus, when a stock hits 5-star territory, we consider it an especially ...

  10. A Favorable Prognosis for This Pharma Stock

    Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.